Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
- 27 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (6) , 1410-1421
Abstract
Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1–4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%–2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%–1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%–1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%–4.52%) in 2018 to 5.39% (95% CI, 4.33%–6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%–.38%) of 4205 PWH. Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.Keywords
Funding Information
- Beijing Municipal Health Commission
- China Capital's
- Funds for Health Improvement and Research (2022-1G-3011)
- Chinese Association of STD and AIDS Prevention and Control
- Liangshan Prefecture “Three Lines and One Network Bottom” Capacity Building Open Small Funding Project (LS2024OR 002)
- Guangzhou Municipal Science and Technology Bureau
- Science and technology project of Guangzhou (2024A03J0883)
- Bureau of Beihai City Science and Technology
- Beihai Science and Technology Planning Project (2020165013)
- Health Commission of Heilongjiang Province
- Scientific Research Project of Heilongjiang Provincial Health Commission (2020-193)
- Jilin Provincial Department of Science and Technology (20230203021SF)
- Health Commission of Gansu Province
- Scientific Research Project of Gansu Provincial Health Commission (GSWSKY2020-22)
- National Natural Science Foundation of China (82260658)
- Guizhou Provincial Department of Science and Technology
- Science and Technology Project of Guizhou Province Qian Ke He Foundation (ZK 2023)
- Beijing Key Laboratory for HIV/AIDS Research (BZ0089)
- Department of Science and Technology of Guangxi Zhuang Autonomous Region
- Guangxi Natural Science Foundation project (2020GXNSFAA159020)
- Public Health Talent Grant Global Health Governance (02-12)
- Capital Health Development Research (2022-2-2185)
- Shanghai Municipal Health Commission (GWVI-11.1-05)
- China Capital's
- Funds for Health Improvement and Research (2022-1G-3015)
- Cultivation Fund of Beijing Center for Disease Prevention and Control (2019-BJYJ-13)
- High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission (2022-2-018, 2022-1-007)
- Guangdong Basic and Applied Basic Research Foundation (2019B1515120003)
- Health Commission of Shenzhen Municipality
- San-Ming Project of Medicine in Shenzhen (SZSM201811071)
- Shenzhen Key Medical Discipline Construction Fund (SZXK064)
- Health Commission of Henan Province
- Cosponsored Construction Project of Provincial Medicine and Technique of Henan Province (LHGJ20191103)
- Department of Science and Technology of Guangdong Province
- Key Area Research and Development Program of Guangdong Province (2022B1111020002)
- Science and Technology Commission of Shanghai Municipality
- Natural Science Foundation of Shanghai Municipality (21ZR1459900)
- Beijing High-Level Public Health Doctor Cultivation Project
- China Capital's
- Funds for Health Improvement and Research (2024-1G-3013)
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- Administrative Commission of Zhongguancun Science Park (D171100006717002)
This publication has 38 references indexed in Scilit:
- Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean EuropeClinical Infectious Diseases, 2022
- Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014–2018Clinical Infectious Diseases, 2021
- Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African CountriesClinical Infectious Diseases, 2020
- The Human Immunodeficiency Virus Care Continuum in China: 1985–2015Clinical Infectious Diseases, 2017
- HIV-1 drug resistance and resistance testingInfection, Genetics and Evolution, 2016
- Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in TaiwanScientific Reports, 2016
- Emerging Trends of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving First-Line Highly Active Antiretroviral Therapy: A Systematic Review and Meta-AnalysisClinical Infectious Diseases, 2014
- Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive IndividualsClinical Infectious Diseases, 2014
- The Prevalence of Drug Resistance Mutations Among Treatment-Naive HIV-Infected Individuals in Beijing, ChinaAIDS Research and Human Retroviruses, 2012
- Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation ClassesThe Journal of Infectious Diseases, 2011